Discontent is growing over new drug pricing re-evaluation system

The government's projected enforcement over the new drug pricing re-evaluation system has overshadowed the domestic pharmaceutical industry with no some proper countermeasures foreseeable, while raising their mounting discontent over the new system.

1) Aftereffects

Pharmaceutical business sources say that since the new system is focusing on the reduction of the insurance drug prices unil...